EGFR and head and neck squamous cell carcinoma: A phase I/Ib study is evaluating first-line treatment in patients with metastatic HNSCC with CPS > 1, the BCA 101, a bifunctional antibody designed to inhibit the EGFR and TGF-β in combination with pembrolizumab.